From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients

Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes?

(2018) M. Ruscica et al.   ANNALS OF MEDICINE

PCSK9 antagonists and inflammation

(2018) Massimiliano Ruscica et al.   ATHEROSCLEROSIS

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

(2018) Paul M Ridker et al.   LANCET

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study

(2018) Knut Tore Lappegård et al.   TRANSFUSION AND APHERESIS SCIENCE

PCSK9 induces a pro-inflammatory response in macrophages

(2018) Chiara Ricci et al.   Scientific Reports

Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs

(2017) Claudia Stefanutti et al.   Journal of Clinical Lipidology

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia

(2017) G. Kees Hovingh et al.   Journal of Clinical Lipidology

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

(2017) Andrea Baragetti et al.   European Journal of Preventive Cardiology

New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials

(2017) Katrina L Ellis et al.   European Journal of Preventive Cardiology

Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?

(2017) Francesco Sbrana et al.   European Journal of Preventive Cardiology

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

(2017) Frederick J Raal et al.   Lancet Diabetes & Endocrinology

PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement

(2016) Nicola Ferri et al.   ATHEROSCLEROSIS

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol

(2016) Knut Tore Lappegård et al.   ATHEROSCLEROSIS

Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms

(2016) Amirhossein Sahebkar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

PCSK9 Association With Lipoprotein(a)Novelty and Significance

(2016) Hagai Tavori et al.   CIRCULATION RESEARCH

From C-Reactive Protein to Interleukin-6 to Interleukin-1

(2016) Paul M Ridker   CIRCULATION RESEARCH

Lipoprotein Apheresis

(2016) Patrick M. Moriarty et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   EUROPEAN HEART JOURNAL

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

(2016) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response

(2016) Knut Tore Lappegård et al.   Journal of Clinical Lipidology

Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia

(2016) Claudia Stefanutti et al.   MEDIATORS OF INFLAMMATION

The Agenda for Familial Hypercholesterolemia

(2015) Samuel S. Gidding et al.   CIRCULATION

Local effects of human PCSK9 on the atherosclerotic lesion

(2015) Ilaria Giunzioni et al.   JOURNAL OF PATHOLOGY

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances

(2014) Claudia Stefanutti et al.   Current Atherosclerosis Reports

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease

(2013) Josef Leebmann et al.   CIRCULATION

Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis

(2013) Hagai Tavori et al.   CIRCULATION RESEARCH

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation

(2013) Tanja Kosenko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy

(2013) Frederick Raal et al.   Journal of the American Heart Association

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

(2011) Anna Roubtsova et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis

(2011) C. Stefanutti et al.   CYTOKINE

Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias

(2011) Claudia Stefanutti et al.   CYTOKINE

Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease

(2009) Paul Elliott   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Different inflammatory responses induced by three LDL-lowering apheresis columns

(2009) Anders Hovland et al.   JOURNAL OF CLINICAL APHERESIS

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Update and Analysis of the University College London Low Density Lipoprotein Receptor Familial Hypercholesterolemia Database

(2008) S. E. A. Leigh et al.   ANNALS OF HUMAN GENETICS

Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity†

(2008) Daping Fan et al.   BIOCHEMISTRY

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

(2008) Janice Mayne et al.   Lipids in Health and Disease

Protein adsorption during LDL-apheresis: proteomic analysis

(2008) H. Dihazi et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE